A5006030842- Venous Thromboembolism Diagnosis and Management
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Atrial Fibrillation Management and Outcomes
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Central Venous Catheters and Hemodialysis
- Platelet Disorders and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- COVID-19 and healthcare impacts
- Viral-associated cancers and disorders
- Hemoglobinopathies and Related Disorders
- Heparin-Induced Thrombocytopenia and Thrombosis
- Acute Lymphoblastic Leukemia research
- Metastasis and carcinoma case studies
- CAR-T cell therapy research
- Bone and Joint Diseases
- Diagnosis and Treatment of Venous Diseases
- Hemophilia Treatment and Research
- Acute Myocardial Infarction Research
- COVID-19 Clinical Research Studies
Sapienza University of Rome
2013-2023
Policlinico Umberto I
2018
COVID-19 infection causes respiratory pathology with severe interstitial pneumonia and extra-pulmonary complications; in particular, it may predispose to thromboembolic disease. The current guidelines recommend the use of thromboprophylaxis patients COVID-19, however, optimal heparin dosage treatment is not well-established. We conducted a multicentre, Italian, retrospective, observational study on admitted ordinary wards, describe clinical characteristic at admission, bleeding thrombotic...
Abstract D-dimer assay is used to stratify patients with unprovoked venous thromboembolism (VTE) for the risk of recurrence. However, this approach was never evaluated since direct oral anticoagulants are available. With multicenter, prospective cohort study, we aimed assess value an algorithm incorporating serial testing and administration reduced-dose apixaban (2.5 mg twice daily) only a positive test. A total 732 outpatients aged 18 74 years, anticoagulated ≥12 months after first VTE,...
Thrombophilia is a condition that predisposes to higher incidence of venous thromboembolisms (VTE), some also in atypical sites. Direct oral anticoagulants (DOACs) have proven be effective the treatment deep vein thrombosis (DVT). However, their use can sometimes challenging particular settings patients such as those with major thrombophilia - antithrombin, protein C and S deficiency, homozygous mutation Factor V Leiden, II G20210A, combined heterozygous factor Leiden G20210A carrying high...
Major surgical societies advised using non-operative management of appendicitis and suggested against laparoscopy during the COVID-19 pandemic. The hypothesis is that a significant reduction in number emergent appendectomies was observed pandemic, restricted to complex cases. study aimed analyse pandemic on national basis compare it same period previous year. This multicentre, retrospective, observational investigating outcomes patients undergoing appendectomy March-April 2019 vs 2020....
Background: Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE). Nowadays, DOACs represent gold standard long-term anticoagulation, with low-intensity administration becoming increasingly worldwide in such scenario. Albeit apixaban rivaroxaban approved clinical usage as VTE prophylaxis, there few literature data regarding their efficacy safety a long follow-up.
 Objectives: The aim our study was to evaluate...
Imatinib has become first line therapy in chronic myeloid leukemia patients. Little is known about the infective consequences during treatment with this drug large series of phase patients.From January 2001 to September 2006 we treated imatinib 250 patients (early CP) or after interferon failure (late CP), out clinical trials and recorded all bacterial viral infections occurred.We a similar incidence both late CP (respectively, 16% 13%) 3.5 years follow-up. Analysis presenting features...
To evaluate follow-up after α-interferon (IFN) discontinuation, 23 patients with chronic myeloid leukemia (CML) in stable complete molecular response (CMolR) IFN were revisited. After a median treatment of 105.8 months (IR 56.1 - 127.3), all discontinued for prolonged CMolR (12), intolerance (8) or planned ABMT (3). 12.5 months, one patient developed an extramedullar blast crisis. Four needed to start imatinib, achieving again response. Eighteen are still off-therapy (median time from...
Both Dasision and ENESTnd trials had many exclusion criteria, with a possible selection bias compared the real-life. To address impact of this on first-line treatment in current clinical practice, we revised 207 unselected newly diagnosed chronic phase myeloid leukaemia (CML) patients [M/F 108/99, median age 58.8 years, interquartile range 42.3-70.2] treated front-line imatinib from June 2002 to 2013 at our Institution, evaluated how them would have been excluded enrolment two trials....
The efficacy and safety of azacitidine in elderly patients (aged >65 years) with myelodysplastic syndromes (MDS) treated outside clinical trials are reported. Thirty-eight MDS received (75 mg/m(2), schedule 5+2 +2): seven were classified as having refractory cytopenia multilineage dysplasia (RCMD), nine anemia excess blasts (RAEB) type 1, 18 RAEB 2 four chronic myelomonocytic leukemia (CMML-2). According to International Working Group (IWG) 2006 criteria, after the first cycles we detected...
In patients with chronic myeloid leukemia (CML) responsive to imatinib, it is still unknown whether the long-lasting treatment could induce appearance of a persistent/late anemia. To highlight this issue, we revised 128 CML (M/F 64/64, median age at diagnosis 56.9 years, interquartile range 43.0-69.3) treated our Institution 1st line imatinib for least 36 months and in stable complete cytogenetic response. At 36th month anemia (Hb < 12 g/dl > 6 months) was present 38/128 (29.6%): moderate 8...
The anticoagulant treatment for patients with hematologic malignancies is low molecular weight heparin (LMWH), which considered the safest in this particular setting. Although direct oral anticoagulants (DOACs) have proven their efficacy and safety cancer, use can be challenging due to peculiarity of these neoplasms: high thrombotic risk, possible onset thrombocytopenia concomitant anticancer therapies. aim our study was evaluate DOACs venous thromboembolism or atrial fibrillation plasmatic...